Results to your Biomarker

Biomarker
Exposure to
Matrix
Analytical Technique
8-iso-PGF2α
Oxidative Stress
Urine
LC-MS/MS

Matching services

tobacco

Tobacco Harm Reduction

Tobacco harm reduction is a public health strategy to lower the health risks to individuals and wider society associated with using tobacco products. Biomarkers specific for the exposure to tobacco and smoke are key endpoints for evaluating new emerging nicotine products with a potentially reduced risk.

Scientific Contribution

publication
April 2018

Suitability of biomarkers of biological effects (BOBEs) for assessing the likelihood of reducing the tobacco related disease risk by new and innovative tobacco products: A literature review

Regulatory Toxicology and Pharmacology, Volume 94, doi: 10.1016/j.yrtph.2018.02.002
publication
March 2018

Analysis of Urinary Eicosanoids by LC-MS/MS Reveals Alterations in the Metabolic Profile after Smoking Cessation

Chemical Research in Toxicology, Volume 31, doi: 10.1021/acs.chemrestox
publication
October 2017

Metabolomic Fingerprinting in Various Body Fluids of a Diet-Controlled Clinical Smoking Cessation Study Using a Validated GC-TOF-MS Metabolomics Platform

Journal of Proteome Research, Volume 16(10), doi: 10.1021/acs.jproteome.7b00128.
publication
January 2018

Review of biomarkers to assess the effects of switching from cigarettes to modified risk tobacco products

Biomarkers, Volume 23(3), doi: 10.1080/1354750X.2017.1419284
publication
February 2012

A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids

Journal of Lipid Research, Volume 53, doi: 10.1194/jlr.D023739
Conference contribution
October 2018

Identifying suitable biomarkers of biological effects (BOBEs) for evaluating reduced risk products

CORESTA Congress 2018, Biomarker Workshop, Kunming, China